The iron load of lipocalin-2 (LCN-2) defines its pro-tumour function in clear-cell renal cell carcinoma
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: We aimed at clarifying the role of lipocalin-2 (LCN-2) in clear-cell renal cell carcinoma (ccRCC). Since LCN-2 was recently identified as a novel iron transporter, we explored its iron load as a decisive factor in conferring its biological function. Methods: LCN-2 expression was analysed at the mRNA and protein level by using immunohistochemistry, RNAscope® and qRT-PCR in patients diagnosed with clear-cell renal cell carcinoma compared with adjacent healthy tissue. We measured LCN-2-bound iron by atomic absorption spectrometry from patient-derived samples and applied functional assays by using ccRCC cell lines, primary cells, and 3D tumour spheroids to verify the role of the LCN-2 iron load in tumour progression. Results: LCN-2 was associated with poor patient survival and LCN-2 mRNA clustered in high- and low-expressing ccRCC patients. LCN-2 protein was found overexpressed in tumour compared with adjacent healthy tissue, whereby LCN-2 was iron loaded. In vitro, the iron load determines the biological function of LCN-2. Iron-loaded LCN-2 showed pro-tumour functions, whereas iron-free LCN-2 produced adverse effects. Conclusions: We provide new insights into the pro-tumour function of LCN-2. LCN-2 donates iron to cells to promote migration and matrix adhesion. Since the iron load of LCN-2 determines its pro-tumour characteristics, targeting either its iron load or its receptor interaction might represent new therapeutic options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Iron and cancer: more ore to be mined
Torti, S. V., & Torti, F. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3495 · Cited by 1,621
Mori, K., Lee, H. T., Rapoport, D., Drexler, I. R., Foster, K., Yang, J., Schmidt-Ott, K. M., Chen, X., Li, J. Y., Weiss, S., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23056 · Cited by 954
A Cell-Surface Receptor for Lipocalin 24p3 Selectively Mediates Apoptosis and Iron Uptake
Devireddy, L. R., Gazin, C., Zhu, X., & Green, M. R. (2005) · Cell · doi:10.1016/j.cell.2005.10.027 · Cited by 672
Habashy, H. O., Powe, D. G., Staka, C. M., Rakha, E. A., Ball, G., Green, A. R., Aleskandarany, M., Paish, E. C., Douglas Macmillan, R., Nicholson, R. I., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0345-x · Cited by 236
Bauer, M., Eickhoff, J. C., Gould, M. N., Mundhenke, C., Maass, N., & Friedl, A. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9619-3 · Cited by 215
An iron regulatory gene signature predicts outcome in breast cancer
Miller, L. D., Coffman, L. G., Chou, J. W., Black, M. A., Bergh, J., D'Agostino, R., Torti, S. V., & Torti, F. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1870 · Cited by 202
Berger, T., Cheung, C. C., Elia, A. J., & Mak, T. W. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000101107 · Cited by 96
Jung, M., Ören, B., Mora, J., Mertens, C., Dziumbla, S., Popp, R., Weigert, A., Grossmann, N., Fleming, I., & Brüne, B. (2016) · Science Signaling · doi:10.1126/scisignal.aaf3241 · Cited by 87
Self-citationMacrophage-derived lipocalin-2 transports iron in the tumor microenvironment
Mertens, C., Mora, J., Ören, B., Grein, S., Winslow, S., Scholich, K., Weigert, A., Malmström, P., Forsare, C., Fernö, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1408751 · Cited by 85
Self-citationMertens, C., Akam, E. A., Rehwald, C., Brüne, B., Tomat, E., & Jung, M. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166164 · Cited by 83
Self-citation
Cited by
Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology
Brown, R. A. M., Richardson, K. L., Kabir, T. D., Trinder, D., Ganss, R., & Leedman, P. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00476 · Cited by 278
Torti, S. V., & Torti, F. M. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100860 · Cited by 153
Shen, P., Jia, Y., Zhou, W., Zheng, W., Wu, Y., Qu, S., Du, S., Wang, S., Shi, H., Sun, J., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.04.010 · Cited by 42
“Recently, LCN-2 has been demonstrated to mediate key roles in drug resistance and immunomodulation of tumor cells via binding siderophore-complexed ferric iron with high affinity 21,22 , making it a potential therapeutic target for regulating the TME of liver cancer.”
BackgroundLipocalin-2 and intestinal diseases
Zhang, Z.-X., Peng, J., & Ding, W.-W. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i46.4864 · Cited by 19
Metadata
- Authors
- Rehwald, C., Schnetz, M., Urbschat, A., Mertens, C., Meier, J. K., Bauer, R., Baer, P., Winslow, S., Roos, F. C., Zwicker, K., Huard, A., Weigert, A., Brüne, B., & Jung, M.
- Venue
- British Journal of Cancer
- Published
- 2019-11-27
- Volume
- 122
- Issue
- 3
- Pages
- 421-433
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2990807229
- Cited by
- 44
- References
- 10
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The iron load of lipocalin-2 (LCN-2) defines its pro-tumour function in clear-cell renal cell carcinoma. https://app.cochat.ai/papers/10.1038/s41416-019-0655-7
- The paper
- Rehwald, C., Schnetz, M., Urbschat, A., Mertens, C., Meier, J. K., Bauer, R., Baer, P., Winslow, S., Roos, F. C., Zwicker, K., Huard, A., Weigert, A., Brüne, B., & Jung, M. (2020). The iron load of lipocalin-2 (LCN-2) defines its pro-tumour function in clear-cell renal cell carcinoma. British Journal of Cancer. https://doi.org/10.1038/s41416-019-0655-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.